Assignee
PROTALIX LTD
IL·15 granted patents·21 pending applications·53 citations·filing 2004–2025
Top patents by PatentIndex Score
36 records- 0194US7951557B2Human lysosomal proteins from plant cell culturePROTALIX LTD·Filed 2007·Granted May 31, 2011·30 cites·16 claims
- 0287US10870842B2Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2019·Granted Dec 22, 2020·2 cites·20 claims
- 0387US10000551B2Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing samePROTALIX LTD·Filed 2015·Granted Jun 19, 2018·5 cites·24 claims
- 0485US2026049297A1Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2025·Application pending·0 cites
- 0584US9708595B2Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2015·Granted Jul 18, 2017·4 cites·20 claims
- 0682US10280414B2Stabilized α-galactosidase and uses thereofPROTALIX LTD·Filed 2017·Granted May 7, 2019·3 cites·20 claims
- 0781US11225648B2Modified DNase and uses thereofPROTALIX LTD·Filed 2016·Granted Jan 18, 2022·4 cites·24 claims
- 0879US12385026B2Stabilized alpha-galactosidase and uses thereofPROTALIX LTD·Filed 2022·Granted Aug 12, 2025·0 cites·16 claims
- 0977US9603907B2Dry powder formulations of dNase IPROTALIX LTD·Filed 2013·Granted Mar 28, 2017·2 cites·20 claims
- 1075US9220737B2Plant cell culture expressing human lysosomal proteins and uses thereofPROTALIX LTD·Filed 2014·Granted Dec 29, 2015·1 cites·7 claims
- 1171US10087232B2Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapyPROTALIX LTD·Filed 2014·Granted Oct 2, 2018·2 cites·24 claims
- 1266US10730925B2Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing samePROTALIX LTD·Filed 2018·Granted Aug 4, 2020·0 cites·26 claims
- 1362US11814657B2Modified DNase and uses thereofPROTALIX LTD·Filed 2021·Granted Nov 14, 2023·0 cites·19 claims
- 1462US2009053762A1Cell/tissue culturing device, system and methodPROTALIX LTD·Filed 2007·Application pending·0 cites
- 1562US2024263150A1Methods of treating diseases associated with elevated uric acidPROTALIX LTD·Filed 2024·Application pending·0 cites
- 1661US2013177538A1Human lysosomal proteins from plant cell culturePROTALIX LTD·Filed 2012·Application pending·0 cites
- 1761US2011159590A1Cell/tissue culturing device, system and methodPROTALIX LTD·Filed 2011·Application pending·0 cites
- 1859US2010136673A1Cell/tissue culturing device, system and methodPROTALIX LTD·Filed 2010·Application pending·0 cites
- 1958US2016095907A1Plant cell culture expressing human lysosomal proteins and uses thereofPROTALIX LTD·Filed 2015·Application pending·0 cites
- 2057US9603906B2Inhalable liquid formulations of DNase IPROTALIX LTD·Filed 2013·Granted Mar 28, 2017·0 cites·19 claims
- 2156US2023416707A1Long-acting dnasePROTALIX LTD·Filed 2021·Application pending·0 cites
- 2253US2016017021A1TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAMEPROTALIX LTD·Filed 2014·Application pending·0 cites
- 2353US2016017020A1Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing samePROTALIX LTD·Filed 2014·Application pending·0 cites
- 2452US12194079B2Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidasePROTALIX LTD·Filed 2018·Granted Jan 14, 2025·0 cites·6 claims
- 2552US2024002814A1Modified uricase and uses thereofPROTALIX LTD·Filed 2021·Application pending·0 cites
- 2651US2014256017A1Saccharide-containing protein conjugates and uses thereofPROTALIX LTD·Filed 2014·Application pending·0 cites
- 2751US2025134968A1Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidasePROTALIX LTD·Filed 2025·Application pending·0 cites
- 2850US2018291084A1Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing samePROTALIX LTD·Filed 2018·Application pending·0 cites
- 2948US2023374447A1Dicer-like knock-out plant cellsPROTALIX LTD·Filed 2021·Application pending·0 cites
- 3046US2015023929A1Oral unit dosage forms and uses of same for the treatment of gaucher diseasePROTALIX LTD·Filed 2013·Application pending·0 cites
- 3144US2011070201A1Mucosal or enteral administration of biologically active macromoleculesPROTALIX LTD·Filed 2006·Application pending·0 cites
- 3244US2006204487A1Production of high mannose proteins in plant culturePROTALIX LTD·Filed 2004·Application pending·0 cites
- 3342US12385054B2Removal of constructs from transformed cellsPROTALIX LTD·Filed 2019·Granted Aug 12, 2025·0 cites·8 claims
- 3442US2025332228A1Methods of treating diseases associated with elevated uric acidPROTALIX LTD·Filed 2025·Application pending·0 cites
- 3540US2013017169A1Multimeric forms of therapeutic proteins and uses thereofPROTALIX LTD·Filed 2011·Application pending·0 cites
- 3637US2017101633A1Method of maintaining disease stability in a subject having gaucher's diseasePROTALIX LTD·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →